1. US Food and Drug Administration. Proposed order: Proposed Order: Reclassification of Surgical Mesh for Transvaginal Pelvic Organ Prolapse Repair and Surgical Instrumentation for Urogynecologic Surgical Mesh Procedures; Designation of Special Controls for Urogynecologic Surgical Mesh Instrumentation. May 1, 2014. Available at: https://www.federalregister.gov/articles/2014/05/01/2014-09907/reclassification-of-surgical-mesh-for-transvaginal-pelvic-organ-prolapse-repair-and-surgical . Accessed 30 Jan 2015.
2. Jonsson Funk M, Levin PJ, Wu JM. Trends in the surgical management of stress urinary incontinence. Obstet Gynecol. 2012;119:845–51.
3. US Food and Drug Administration. FDA safety communication: update on serious complications associated with transvaginal placement of surgical mesh in repair of pelvic organ prolapse. July 13, 2011. Available at: http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm262435.htm . Accessed 10 Feb 2015.
4. Rogowski A, Bienkowski P, Tosiak A, et al. Mesh retraction correlates with vaginal pain and overactive bladder symptoms after anterior vaginal mesh repair. Int Urogynecol J. 2013;24(12):2087–92.
5. Skala CE, Renezeder K, Albrich S, et al. Mesh complications following prolapse surgery: management and outcome. Eur J Obstet Gynecol Reprod Biol. 2011;159:453–6.